Immunovant, Inc. (IMVT) News
Follow Immunovant, Inc. (IMVT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Immunovant Q2 Net Loss Narrows on Lower R&D Costs
EQUITY | Nov 09, 2026, 12:17 PM UTC
M
Immunovant Reports $97.2 Million Quarterly Loss and IMVT-1402 Trial Results
Immunovant reported a net loss of $97.2 million, or $0.47 per share, for the quarter ended September 30, 2026, versus a $126.5 million loss a year earlier. Cash and cash equivalents totaled $722.3 million at quarter-end.
EQUITY | Nov 09, 2026, 12:13 PM UTC
M
Immunovant Q2'26 Earnings Preview Lists Revenue Estimate
Immunovant is scheduled to report Q2'26 results on November 9 before the market opens. Revenue is estimated at zero, with EPS anticipated at $(0.74).
EQUITY | Nov 02, 2026, 12:00 PM UTC
M
Immunovant Expects Brepocitinib Launch by End of September
Immunovant CEO Matthew Gline said the company expects to launch brepocitinib by the end of September, pending FDA action. The company also reported enrollment in a phase 3 cutaneous sarcoidosis study and outlined anticip
EQUITY | Oct 14, 2026, 08:59 AM UTC
H
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Applied Digital Corp (NASDAQ: APLD ) rose sharply in pre-market trading after the company posted better-than-expected financial results for the first quarter. Applied Digital reported first-quarter adjusted rev
LIVE | Oct 08, 2026, 08:32 AM UTC
L
Weekly Recap: Cash to fund potential IMVT-1402 launch and 5% stock drop
Immunovant Inc (NASDAQ:IMVT) said cash fell to $797.8M on June 30 from $902.1M but should fund operations through a potential commercial launch of IMVT-1402 for Graves’ disease, while shares slid about 5% after results a
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program — Barrons.com
By Mackenzie TatananniImmunovant shares were on track for their worst session in over a year after the biotech said it was halting development of its experimental autoimmune drug in one indication following a trial miss.
EQUITY | Sep 23, 2026, 05:45 PM UTC
L
Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint
By Chris WackImmunovant said it saw negative topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 imeroprubart for the treatment of cutaneous lupus erythematosus.The company said the study did
NEWS | Sep 23, 2026, 02:19 PM UTC
L
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Shares of Immunovant (IMVT) fell about 6% on Wednesday after its lead drug candidate failed to meet the primary goal of a proof-of-concept study in a form of lupus, prompting the company to stop developing the therapy fo
EQUITY | Sep 23, 2026, 12:33 PM UTC
L
Immunovant, Inc. (IMVT) Halts CLE Program After IMVT-1402 Misses Primary Endpoint
Immunovant said IMVT-1402 did not achieve statistical significance on the primary endpoint in its CLE proof-of-concept study and plans to stop development in CLE. Numerical trends favored IMVT-1402; other autoimmune indi
NEWS | Sep 23, 2026, 11:03 AM UTC
L
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant NASDAQ:ROIV today announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 (imeroprubart)
NEWS | Sep 23, 2026, 11:03 AM UTC
L
IMVT - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
IMVT - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
NEWS | Sep 23, 2026, 11:01 AM UTC
H
Immunovant Q1 2027 Earnings Call: Complete Transcript
On Thursday, Immunovant (NASDAQ: IMVT ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entir
LIVE | Sep 17, 2026, 12:18 PM UTC
L
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
EARNINGS | Aug 06, 2026, 11:01 AM UTC
L
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ: IMVT ) with a Buy and raises the price target from $57 to $61.
EQUITY | Jun 30, 2026, 06:49 PM UTC